Bacillus calmette-guerin substrain tice live antigen
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Bacillus calmette-guerin substrain tice live antigen is a live attenuated vaccine against Mycobacterium bovis.
- Brand Names
- BCG Vaccine, Tice Bcg
- Generic Name
- Bacillus calmette-guerin substrain tice live antigen
- DrugBank Accession Number
- DB10343
- Background
Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis for percutaneous use. It is administered to prevent the development of tuberculosis.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- BCG, Live, Tice Strain
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abatacept. Acyclovir The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Adalimumab. Adefovir dipivoxil The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Adefovir dipivoxil. Aldesleukin The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Aldesleukin. Alefacept The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alefacept. Alemtuzumab The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alemtuzumab. Altretamine The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Altretamine. Amantadine The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Amantadine. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bcg Vaccine Injection, powder, lyophilized, for solution 50 mg/1 Percutaneous Merck Sharp & Dohme Corp. 1989-06-21 Not applicable US 
Oncotice Powder, for solution 50 mg/1 Intravesical Merck Ltd. 1995-12-31 Not applicable Canada 
Tice Bcg Powder, for suspension 50 mg/50mL Intravesical Merck Sharp & Dohme Corp. 1990-08-24 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 2XQ558L16Z
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Stage 0 Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Urothelial Carcinoma 1 3 Recruiting Treatment Bladder Cancer, Cancer 3 3 Recruiting Treatment High-Risk Non-Muscle-Invasive Bladder Cancer 1 3 Withdrawn Prevention Coronavirus Disease 2019 (COVID‑19) 1 2 Recruiting Supportive Care Bladder Urothelial Carcinoma In Situ / Stage 0a Bladder Cancer AJCC v8 / Stage 0is Bladder Cancer AJCC v8 / Stage I Bladder Cancer AJCC v8 / Superficial Bladder Urothelial Carcinoma / Urothelial Carcinoma Bladder Recurrent 1 2, 3 Not Yet Recruiting Treatment Metastatic Cutaneous Melanoma 1 1 Active Not Recruiting Treatment Recurrent Bladder Carcinoma / Stage 0a Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Cancer 1 1 Completed Treatment Bladder Cancer, Cancer 1 1 Completed Treatment Transitional Cell Carcinoma of Bladder 1 1, 2 Completed Treatment Bladder Cancer, Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Percutaneous 50 mg/1 Injection, powder, for suspension Intravesical Powder, for solution Intravesical 50 mg/1 Powder, for suspension Intravesical 50 mg/50mL Injection, powder, lyophilized, for suspension 50 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 01, 2015 20:03 / Updated on July 28, 2021 07:24